Protagenic Therapeutics, Inc.\new Proceeds from Debt, Net of Issuance Costs
Protagenic Therapeutics, Inc.\new (PTIX) reported Proceeds from Debt, Net of Issuance Costs of $327.13 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2023-03-31
- Protagenic Therapeutics, Inc.\new proceeds from debt, net of issuance costs for the quarter ending 2021-12-31 was $0.00.
- Protagenic Therapeutics, Inc.\new proceeds from debt, net of issuance costs for the quarter ending 2021-09-30 was $0.00.
- Protagenic Therapeutics, Inc.\new proceeds from debt, net of issuance costs for fiscal 2021 was $327.13K.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $327.13K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $327.13K 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | $327.13K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |